Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All convalescent plasma..
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality, day 28 -38% Improvement Relative Risk Mortality, day 14 -100% Improvement -11% Hospitalization time -67% Conv. Plasma  PLACOVID  LATE TREATMENT  RCT Is late treatment with convalescent plasma beneficial for COVID-19? RCT 160 patients in Brazil (July - December 2020) Higher mortality with convalescent plasma (not stat. sig., p=0.42) c19early.org Sekine et al., European Respiratory J., Jul 2021 Favors conv. plasma Favors control

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial

Sekine et al., European Respiratory Journal, doi:10.1183/13993003.01471-2021, PLACOVID, NCT04547660
Jul 2021  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 160 hospitalized patients in Brazil, showing no significant difference in outcomes with convalescent plasma.
risk of death, 38.5% higher, RR 1.38, p = 0.42, treatment 18 of 80 (22.5%), control 13 of 80 (16.2%), day 28.
risk of death, 100% higher, RR 2.00, p = 0.28, treatment 10 of 80 (12.5%), control 5 of 80 (6.2%), day 14.
risk of no improvement, 10.7% higher, RR 1.11, p = 0.74, treatment 31 of 80 (38.8%), control 28 of 80 (35.0%), day 28.
hospitalization time, 66.7% higher, relative time 1.67, p = 0.87, treatment 80, control 80.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sekine et al., 8 Jul 2021, Randomized Controlled Trial, Brazil, peer-reviewed, 28 authors, study period 15 July, 2020 - 10 December, 2020, average treatment delay 10.0 days, trial NCT04547660 (history) (PLACOVID).
Contact: azavascki@hcpa.edu.br, permissions@ersnet.org.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
Leo Sekine, Beatriz Arns, Bruna R Fabro, Murillo M Cipolatt, Rafael R G Machado, Edison L Durigon, Edino Parolo, José Augusto S Pellegrini, Marina V Viana, Patrícia Schwarz, Thiago C Lisboa, José Miguel S Dora, Julia P Portich, Alessandra A Paz, Lucia Silla, Almeri M Balsan, Felipe Da-Silva Schirmer, Juliana P M Franz, Luciana M Da-Silveira, Raquel C Breunig, Viviana Petersen, Monalisa Sosnoski, Nanci F Mesquita, Fabiana Caroline Z Volpato, Daniel Sganzerla, Maicon Falavigna, Regis G Rosa, Alexandre P Zavascki
European Respiratory Journal, doi:10.1183/13993003.01471-2021
In this open-label, randomised clinical trial, two infusions of convalescent plasma therapy plus standard of care compared to standard of care did not result in higher proportion of clinical improvement on day 28 in patients with severe COVID-19 https://bit.ly/2TXuB6S
References
Agarwal, Mukherjee, Kumar, Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Casadevall, Pirofski, The convalescent sera option for containing COVID-19, J Clin Invest
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Horby, Estcourt, Peto, Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Janiaud, Axfors, Schmitt, Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis, JAMA
Joyner, Bruno, Klassen, Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients, Mayo Clin Proc
Joyner, Carter, Senefeld, Convalescent plasma antibody levels and the risk of death from COVID-19, N Engl J Med
Li, Zhang, Hu, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA
Libster, Marc, Wappner, Early high-titer plasma therapy to prevent severe Covid-19 in older adults, N Engl J Med
Lundgren, Grund, Barkauskas, A neutralizing monoclonal antibody for hospitalized patients with COVID-19, N Engl J Med
Rosner, Fundamentals of Biostatistics
Simonovich, Pratx, Scibona, A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med
Wendel, Kutner, Machado, Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: preliminary lessons from a voluntary convalescent donor program, Transfusion
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit